In the last month of 2020, the global epidemic of COVID-19 (a pneumonia disease caused by SARS-CoV-2 infection) will continue. This winter and next spring, the epidemic of COVID-19 and influenza and other respiratory infectious diseases may overlap. In the opinion of many epidemiologists, the co-infection of influenza virus and SARS-CoV-2 may become the biggest challenge to the prevention and control of COVID-19 this winter.

CUSABIO, keeping up with the research hotspot, is committed to provide the best products and related custom service to researchers so that they can have a good starting for the next breakthrough. Here, we collect the protein products of SARS-CoV-2 and influenza virus, and hope they can help you in related research. These proteins are validated in bioactivity with high purity.

The Hot Protein Products of SARS-CoV-2

The Hot Protein Products of Influenza Virus

Other Featured Protein

Recombinant Human SARS-CoV-2 Nucleoprotein, Biotinylated (CSB-EP3325GMY-B)

Recombinant Human SARS-CoV-2 Spike glycoprotein, partial, Biotinylated (CSB-MP3324GMY1-B)

Recombinant Human SARS-CoV-2 Spike glycoprotein (V367F), partial (CSB-MP3324GMY1(M1))

Recombinant Human SARS-CoV-2 Spike glycoprotein (G476S), partial (CSB-MP3324GMY1(M4))

Recombinant Human SARS-CoV-2 Spike glycoprotein (V483A), partial (CSB-MP3324GMY1(M5))